How to reach LDL targets quickly in patients with diabetes or metabolic syndrome

Lawrence A. Leiter, Pierre Martineau, Eduardo De Teresa, C. Farsang, Allan Gaw, GianFranco Gensini, Anatoly Langer

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Purpose: To investigate whether using an algorithm to select the starting dose of a statin according to baseline and target LDL-cholesterol (LDL-C) values would facilitate achieving lipid targets in patients with diabetes or the metabolic syndrome. Methods: Two 12-week, prospective, open-label trials enrolled 2717 high-risk subjects, of whom 1024 had diabetes and 1251 had metabolic syndrome. Subjects with LDL-C between 100 and 220 mg/dL (2.6-5.7 mmol/L) were assigned a starting dose of atorvastatin (10, 20, 40, or 80 mg/d) based on LDL-C level and status of statin use at baseline (statin-free [SF] or statin-treated [ST]), with a single uptitration at 6 weeks, if required. Results: Among patients with diabetes, 81 % of SF subjects (82%, 84%, 82%, and 76% with 10, 20, 40, and 80 mg, respectively) and 60% of ST subjects (61%, 68%, and 47% with 20, 40, and 80 mg, respectively) achieved LDL-C target. Among patients with metabolic syndrome, 78% of SF subjects (81%, 84%, 82%, and 66% with 10, 20, 40, and 80 mg, respectively) and 57% of ST subjects (58%, 70%, and 47% with 20, 40, and 80 mg, respectively) achieved LDL-C target. Among ST subjects, we observed reductions in LDL-C with atorvastatin beyond those achieved with other statins used at baseline in patients with diabetes and patients with metabolic syndrome. Atorvastatin was well tolerated. Conclusions: The ACTFAST studies confirm that a targeted starting dose of atorvastatin allows most patients with type 2 diabetes or the metabolic syndrome to achieve their LDL-C target safely with the initial dose or just a single titration. This therapeutic strategy may help overcome the treatment gap still observed in the treatment of lipids in diabetes.

Original languageEnglish
Pages (from-to)661-668
Number of pages8
JournalJournal of Family Practice
Volume57
Issue number10
Publication statusPublished - Oct 2008

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
LDL Cholesterol
oxidized low density lipoprotein
Lipids
Type 2 Diabetes Mellitus
Therapeutics

ASJC Scopus subject areas

  • Family Practice

Cite this

Leiter, L. A., Martineau, P., De Teresa, E., Farsang, C., Gaw, A., Gensini, G., & Langer, A. (2008). How to reach LDL targets quickly in patients with diabetes or metabolic syndrome. Journal of Family Practice, 57(10), 661-668.

How to reach LDL targets quickly in patients with diabetes or metabolic syndrome. / Leiter, Lawrence A.; Martineau, Pierre; De Teresa, Eduardo; Farsang, C.; Gaw, Allan; Gensini, GianFranco; Langer, Anatoly.

In: Journal of Family Practice, Vol. 57, No. 10, 10.2008, p. 661-668.

Research output: Contribution to journalArticle

Leiter, LA, Martineau, P, De Teresa, E, Farsang, C, Gaw, A, Gensini, G & Langer, A 2008, 'How to reach LDL targets quickly in patients with diabetes or metabolic syndrome', Journal of Family Practice, vol. 57, no. 10, pp. 661-668.
Leiter LA, Martineau P, De Teresa E, Farsang C, Gaw A, Gensini G et al. How to reach LDL targets quickly in patients with diabetes or metabolic syndrome. Journal of Family Practice. 2008 Oct;57(10):661-668.
Leiter, Lawrence A. ; Martineau, Pierre ; De Teresa, Eduardo ; Farsang, C. ; Gaw, Allan ; Gensini, GianFranco ; Langer, Anatoly. / How to reach LDL targets quickly in patients with diabetes or metabolic syndrome. In: Journal of Family Practice. 2008 ; Vol. 57, No. 10. pp. 661-668.
@article{367004410802485aa59214ccff1a5d5d,
title = "How to reach LDL targets quickly in patients with diabetes or metabolic syndrome",
abstract = "Purpose: To investigate whether using an algorithm to select the starting dose of a statin according to baseline and target LDL-cholesterol (LDL-C) values would facilitate achieving lipid targets in patients with diabetes or the metabolic syndrome. Methods: Two 12-week, prospective, open-label trials enrolled 2717 high-risk subjects, of whom 1024 had diabetes and 1251 had metabolic syndrome. Subjects with LDL-C between 100 and 220 mg/dL (2.6-5.7 mmol/L) were assigned a starting dose of atorvastatin (10, 20, 40, or 80 mg/d) based on LDL-C level and status of statin use at baseline (statin-free [SF] or statin-treated [ST]), with a single uptitration at 6 weeks, if required. Results: Among patients with diabetes, 81 {\%} of SF subjects (82{\%}, 84{\%}, 82{\%}, and 76{\%} with 10, 20, 40, and 80 mg, respectively) and 60{\%} of ST subjects (61{\%}, 68{\%}, and 47{\%} with 20, 40, and 80 mg, respectively) achieved LDL-C target. Among patients with metabolic syndrome, 78{\%} of SF subjects (81{\%}, 84{\%}, 82{\%}, and 66{\%} with 10, 20, 40, and 80 mg, respectively) and 57{\%} of ST subjects (58{\%}, 70{\%}, and 47{\%} with 20, 40, and 80 mg, respectively) achieved LDL-C target. Among ST subjects, we observed reductions in LDL-C with atorvastatin beyond those achieved with other statins used at baseline in patients with diabetes and patients with metabolic syndrome. Atorvastatin was well tolerated. Conclusions: The ACTFAST studies confirm that a targeted starting dose of atorvastatin allows most patients with type 2 diabetes or the metabolic syndrome to achieve their LDL-C target safely with the initial dose or just a single titration. This therapeutic strategy may help overcome the treatment gap still observed in the treatment of lipids in diabetes.",
author = "Leiter, {Lawrence A.} and Pierre Martineau and {De Teresa}, Eduardo and C. Farsang and Allan Gaw and GianFranco Gensini and Anatoly Langer",
year = "2008",
month = "10",
language = "English",
volume = "57",
pages = "661--668",
journal = "Journal of Family Practice",
issn = "0094-3509",
publisher = "Appleton-Century-Crofts",
number = "10",

}

TY - JOUR

T1 - How to reach LDL targets quickly in patients with diabetes or metabolic syndrome

AU - Leiter, Lawrence A.

AU - Martineau, Pierre

AU - De Teresa, Eduardo

AU - Farsang, C.

AU - Gaw, Allan

AU - Gensini, GianFranco

AU - Langer, Anatoly

PY - 2008/10

Y1 - 2008/10

N2 - Purpose: To investigate whether using an algorithm to select the starting dose of a statin according to baseline and target LDL-cholesterol (LDL-C) values would facilitate achieving lipid targets in patients with diabetes or the metabolic syndrome. Methods: Two 12-week, prospective, open-label trials enrolled 2717 high-risk subjects, of whom 1024 had diabetes and 1251 had metabolic syndrome. Subjects with LDL-C between 100 and 220 mg/dL (2.6-5.7 mmol/L) were assigned a starting dose of atorvastatin (10, 20, 40, or 80 mg/d) based on LDL-C level and status of statin use at baseline (statin-free [SF] or statin-treated [ST]), with a single uptitration at 6 weeks, if required. Results: Among patients with diabetes, 81 % of SF subjects (82%, 84%, 82%, and 76% with 10, 20, 40, and 80 mg, respectively) and 60% of ST subjects (61%, 68%, and 47% with 20, 40, and 80 mg, respectively) achieved LDL-C target. Among patients with metabolic syndrome, 78% of SF subjects (81%, 84%, 82%, and 66% with 10, 20, 40, and 80 mg, respectively) and 57% of ST subjects (58%, 70%, and 47% with 20, 40, and 80 mg, respectively) achieved LDL-C target. Among ST subjects, we observed reductions in LDL-C with atorvastatin beyond those achieved with other statins used at baseline in patients with diabetes and patients with metabolic syndrome. Atorvastatin was well tolerated. Conclusions: The ACTFAST studies confirm that a targeted starting dose of atorvastatin allows most patients with type 2 diabetes or the metabolic syndrome to achieve their LDL-C target safely with the initial dose or just a single titration. This therapeutic strategy may help overcome the treatment gap still observed in the treatment of lipids in diabetes.

AB - Purpose: To investigate whether using an algorithm to select the starting dose of a statin according to baseline and target LDL-cholesterol (LDL-C) values would facilitate achieving lipid targets in patients with diabetes or the metabolic syndrome. Methods: Two 12-week, prospective, open-label trials enrolled 2717 high-risk subjects, of whom 1024 had diabetes and 1251 had metabolic syndrome. Subjects with LDL-C between 100 and 220 mg/dL (2.6-5.7 mmol/L) were assigned a starting dose of atorvastatin (10, 20, 40, or 80 mg/d) based on LDL-C level and status of statin use at baseline (statin-free [SF] or statin-treated [ST]), with a single uptitration at 6 weeks, if required. Results: Among patients with diabetes, 81 % of SF subjects (82%, 84%, 82%, and 76% with 10, 20, 40, and 80 mg, respectively) and 60% of ST subjects (61%, 68%, and 47% with 20, 40, and 80 mg, respectively) achieved LDL-C target. Among patients with metabolic syndrome, 78% of SF subjects (81%, 84%, 82%, and 66% with 10, 20, 40, and 80 mg, respectively) and 57% of ST subjects (58%, 70%, and 47% with 20, 40, and 80 mg, respectively) achieved LDL-C target. Among ST subjects, we observed reductions in LDL-C with atorvastatin beyond those achieved with other statins used at baseline in patients with diabetes and patients with metabolic syndrome. Atorvastatin was well tolerated. Conclusions: The ACTFAST studies confirm that a targeted starting dose of atorvastatin allows most patients with type 2 diabetes or the metabolic syndrome to achieve their LDL-C target safely with the initial dose or just a single titration. This therapeutic strategy may help overcome the treatment gap still observed in the treatment of lipids in diabetes.

UR - http://www.scopus.com/inward/record.url?scp=53849088235&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=53849088235&partnerID=8YFLogxK

M3 - Article

C2 - 18842192

AN - SCOPUS:53849088235

VL - 57

SP - 661

EP - 668

JO - Journal of Family Practice

JF - Journal of Family Practice

SN - 0094-3509

IS - 10

ER -